Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMG 701 |
| Synonyms | |
| Therapy Description |
AMG 701 is a bi-specific T-cell engager (BiTE) antibody that simultaneously binds to BCMA (TNFRSF17) and CD3, and activates cytotoxic T-lymphocytes against tumor cells expressing BCMA, potentially inducing death of BCMA expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMG 701 | AMG-701|AMG701|BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody AMG 701 | CD3 Antibody 119 TNFRSF17 Antibody 22 | AMG 701 is a bi-specific T-cell engager (BiTE) antibody that simultaneously binds to BCMA (TNFRSF17) and CD3, and activates cytotoxic T-lymphocytes against tumor cells expressing BCMA, potentially inducing death of BCMA expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03287908 | Phase I | AMG 701 | A Phase 1/2 Study of AMG 701 in Subjects With Multiple Myeloma | Terminated | USA | NLD | DEU | CAN | AUS | 1 |